思创医惠科技股份有限公司 远期结售汇交易内部控制制度 （2025 年 8 月修订） 第一章 总 则 第一条 为规范思创医惠科技股份有限公司（以下简称"公司"）远期结售汇 业务，防范国际贸易业务中的汇率风险，根据《中华人民共和国公司法》《中华人 民共和国证券法》《结汇、售汇及付汇管理规定》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《上市公司信息披露管理办法》及《公司章程》等有关规定，结合公司具 体情况，特制定本制度。 第二条 本制度所称远期结售汇是指银行与客户签订远期结售汇合约，约定 将来办理结汇或售汇的外汇币种、金额、汇率和期限，在到期日外汇收入或支出 发生时，再按照该远期结售汇合同约定的币种、金额、汇率办理的结汇或售汇 业务。 第三条 公司远期结售汇行为除遵守国家相关法律、法规及规范性文件的规 定外，还应遵守本制度的相关规定。 第二章 远期结售汇业务操作规定 第四条 公司只能与经国家外汇管理局和中国人民银行批准、具有远期结售 汇业务经营资格的金融机构进行交易，不得与前述金融机构之外的其他组织或 个人进行远期交易。 第五条 公司进行远期结 ...

思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开 第六届董事会第十次会议，审议了《关于拟购买董高责任险的议案》，为进一步 完善公司风险管理体系，降低公司运营风险，促进公司董事、高级管理人员在各 自职责范围内更充分地行使权利、履行职责，维护公司和投资者的权益，根据《上 市公司治理准则》的有关规定，公司拟为公司及全体董事、高级管理人员及相关 责任人员购买董事及高级管理人员责任险（以下简称"责任险"）。 由于公司全体董事、高级管理人员均为被保险对象，属于利益相关方，根据 《上市公司治理准则》《公司章程》等相关规定，公司全体董事在审议本事项时 已回避表决，本事项将直接提交公司 2025 年第四次临时股东会审议。本事项已 经公司第六届董事会薪酬与考核委员会第三次会议审议，全体委员已回避表决。 现将相关情况公告如下： 一、责任险具体方案 1、投保人：思创医惠科技股份有限公司 证券代码：300078 证券简称：思创医惠 公告编号：2025-094 思创医惠科技股份有限公司 关于拟购买董高责任险的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-092 思创医惠科技股份有限公司 关于 2025 年半年度募集资金存放、管理与使用情况的专项 报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 21 日召开了第六届董事会第十次会议，审议通过了《关于<2025 年半年度募 集资金存放、管理与使用情况的专项报告>的议案》，该议案已经董事会审计委 员会审议通过。 根据中国证券监督管理委员会《上市公司募集资金监管规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳证 券交易所创业板上市公司自律监管指南第 2 号——公告格式》的有关规定，将公 司截至 2025 年 6 月 30 日的募集资金存放、管理与使用情况报告如下： 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 1.非公开发行股票募集资金 根据中国证券监督管理委员会《关于核准思创医惠科技股份有限公司非公开 发行股票的批复》（证监许可〔2019〕1442 号）核准， ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-093 思创医惠科技股份有限公司 的收益进行再投资的相关金额）不应超过投资额度。在上述额度内，资金可以循 环滚动使用。 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好、风险较低的投资产品。 2、投资金额：拟使用总额不超过 80,000 万元人民币（含本数）的闲置自有 资金进行现金管理。 3、特别风险提示：受政策风险、信用风险、流动性风险等因素影响，投资 收益具有不确定性，敬请广大投资者注意投资风险。 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开 第六届董事会第十次会议，审议通过了《关于使用部分闲置自有资金进行现金管 理的议案》，同意公司及子公司在确保不影响正常经营和资金安全的情况下，使 用额度合计不超过 80,000 万元人民币（含本数）的闲置自有资金进行现金管理， 用于择机购买安全性高、流动性好、风险较低的投资产品，使用期限自股东会审 议通过之日起 12 个月内有效 ...

非经营性资金占用及其他关联资金往来情况汇总表 2025年半年度 | 编制单位：思创医惠科技股份有限公司 | | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 关联关系 | 上市公司核算的会 计科目 | 2025年期初 占用资金余额 | 2025年半年度占用 累计发生金额 （不含利息） | 2025年半年度占 用资金的利息 （如有） | 2025年半年度 偿还累计发生 金额 | 2025年6月期末 占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | | | 前控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | - | - | ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-096 思创医惠科技股份有限公司 关于修订、制定及废止公司部分治理制度的公告 其中序号 1 至 7 对应制度尚需提请公司 2025 年第四次临时股东会审议通过 后方能生效；序号 8 至 12 对应制度经公司董事会审议通过后即生效；序号 13 至 15 对应制度经公司董事会审议通过后即废止。修订后的治理制度详见公司于 同日披露于巨潮资讯网（www.cninfo.com.cn）的制度全文，敬请广大投资者查 阅。 特此公告。 思创医惠科技股份有限公司董事会 2025 年 8 月 23 日 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开 第六届董事会第十次会议，审议通过了《关于修订、制定及废止公司部分治理制 度的议案》，现将相关情况公告如下： 一、本次修订、制定及废止部分治理制度的原因及依据 为进一步完善公司法人治理结构，优化内控制度体系，提高公司规范运作水 平，公司根据中国证券监督管理委员会和深圳证券交易所最新发布的相关法律、 法规、规范性文件以及公司于近期修订完成的最新《公司章程》，对公司部分治 理制度进行了系统性 ...

思创医惠科技股份有限公司 2025 年半年度报告全文 思创医惠科技股份有限公司 2025 年半年度报告 2025-090 2025 年 8 月 1 思创医惠科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人许益冉、主管会计工作负责人钱本成及会计机构负责人(会计 主管人员)李秀云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告如有涉及未来计划等前瞻性陈述，均不构成公司对任何投 资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风 险。 公司在经营管理中可能面临的主要风险与相应举措已在本报告第三节 "管理层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述。 敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 02 ...

Core Insights - The stock price of Sichuang Medical has plummeted due to a criminal investigation initiated by the Hangzhou Public Security Bureau regarding fraudulent securities issuance, marking another significant crisis for the company after a hefty fine of 85.7 million yuan imposed by the Zhejiang Securities Regulatory Bureau last year [1][2]. Financial Fraud - Regulatory investigations have uncovered a chain of fraud involving Sichuang Medical, where in 2020, the company inflated profits by 83.94 million yuan, accounting for 67% of the total profit for that period, through its wholly-owned subsidiary, Yihui Technology [2]. Business Impact - The repercussions of the fraud have severely affected the core business of Yihui Technology, which has faced repeated failures in public hospital tenders due to reputational damage. The company's revenue is projected to drop to 169 million yuan in 2024, with a net loss of 320 million yuan, representing a nearly 60% decline from 417 million yuan in 2022 [3]. Strategic Restructuring - On May 30, Sichuang Medical announced the sale of Yihui Technology to a state-owned enterprise for nearly 300 million yuan, marking a complete exit from the smart healthcare sector. The company stated that the divestiture was necessary to concentrate resources on developing business intelligence [4]. Transition Challenges - Following the focus shift to business intelligence, Sichuang Medical aims to leverage its leading global EAS hard tag production capacity and RFID technology. However, the business intelligence segment is expected to see a revenue decline of 15% in 2024, with a gross margin drop of 4.83 percentage points to 21.54%. Despite an increase in revenue share to 72.5%, growth momentum remains insufficient [5].

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is under investigation for suspected fraudulent issuance of securities, with the case currently in the police investigation stage [1] Group 1: Investigation and Legal Issues - The investigation is closely related to previous financial fraud cases, where Sichuang Medical inflated revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflated revenue by 60.96 million yuan and profits by 52.37 million yuan in 2020, accounting for 20.03% and 56.81% of the respective profits [2] - The fraudulent data was included in the annual reports for 2019 and 2020, which were used as important evidence for the issuance of 817 million yuan in convertible bonds in 2021 [3] - The company has faced significant penalties, including a fine of 85.7 million yuan and a 10-year market ban for the former chairman [3] Group 2: Corporate Restructuring - In response to regulatory pressure, the company has made significant adjustments to its ownership structure and business layout, including the resignation of the former chairman and the transfer of control to the Cangnan County Finance Bureau [3] - The company has also divested its subsidiary, Medical Technology Co., which was the main platform for the financial fraud, and has shifted its focus to the Internet of Things sector [4] Group 3: Financial Performance - The company has reported continuous losses, with net profits of -878 million yuan, -874 million yuan, -502 million yuan, and -19.56 million yuan for the years 2022 to 2025 Q1, with a 71.14% reduction in losses for Q1 2025 compared to the same period last year [4] - The company claims that its financial situation has improved since the entry of state-owned capital, with a reduction in losses since 2024 [4] Group 4: Regulatory Environment - The capital market has intensified its crackdown on financial fraud and fraudulent issuance, with a focus on establishing a comprehensive accountability mechanism involving administrative, civil, and criminal responsibilities [5][6] - The ongoing investigation into Sichuang Medical is closely monitored by investors, with the company actively cooperating with the police and preparing compensation plans for affected investors [6]

Core Viewpoint - Sichuang Medical's fraudulent issuance of securities has led to administrative penalties and ongoing criminal investigations, raising concerns about the company's governance and financial stability [1][6][7] Group 1: Fraudulent Issuance and Penalties - Sichuang Medical was penalized by the Zhejiang Securities Regulatory Commission in January 2024 for fraudulent issuance of securities, resulting in fines totaling 85.7 million yuan and a 10-year market ban for the former chairman [4][5] - The fraudulent activities included inflating revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflating revenue by 96.47 million yuan and profits by 83.94 million yuan in 2020 [3][4] Group 2: Ongoing Investigations - The Hangzhou Public Security Bureau has initiated a criminal investigation into the fraudulent issuance case, indicating potential criminal charges against responsible individuals [6][7] - The company has stated that the investigation is still in progress and does not currently have a significant impact on its operations [2][6] Group 3: Corporate Governance Changes - Following the fraud case, Sichuang Medical underwent significant governance changes, including the exit of key personnel and the entry of state-owned investors, which has led to a more stable operational environment [2][5] - The company reported a decline in revenue from 11.16 billion yuan in 2021 to 6.91 billion yuan in 2024, with net losses persisting over the years [4][5] Group 4: Market Reactions - The news of the criminal investigation led to a 10.08% drop in Sichuang Medical's stock price on August 18 [6][7] - The resignation of the vice president due to personal reasons amid the ongoing investigation has raised further speculation in the market [7]